Pioneering Advances in Care and Education (PACE)

Inclusion Criteria

• •Male \>=18 years of age and newly diagnosed prostate cancer (PCa) (within 3-months).
• •Documentation of a low-risk PCa diagnosis as evidenced by clinical features of the following criteria:
• •* PSA test at diagnosis \<=15 ng/ml
• •* Localized PCa (cT1/T2,N0,M0)
• •* Biopsy Gleason grade 2-6 OR (or 3+4 AND \<=33% cores are positive for adenocarcinoma)
• •\*\*\*A minimum of 10 diagnostic cores taken by a systematic directed approach. Sampling may be obtained by target transrectal ultrasound (TRUS) or MRI imaging.
• •* No treatment yet
• •* No previous radiation or simultaneous use of androgen deprivation
• •* Prior use of 5-alpha reductase inhibitor is allowed if they have been stopped for 6 or more months and biopsy performed when patient was not taking the drug
• •* English language proficient and ability to provide informed consent
• •* Managing urologist considers them a candidate for active surveillance
• •Written informed consent (and assent when applicable) obtained from subject and ability for subject to comply with the requirements of the study, including the ability to read and speak English.
• •1. have pursued any active therapy for prostate cancer will be excluded;
• •2. are unable to read/speak English; or
• •3. if their managing urologist does NOT deem them as a candidate for active surveillance.